How Much Does KRAS, NRAS,BRAF mutation testing Cost in Istanbul?
| Turkey | Thailand | |
|---|---|---|
| KRAS, NRAS,BRAF mutation testing | from AUD $2,200 | ≈ AUD $810 |
Your Benefits and Guarantees with Bookimed
Transparent Prices & Flexible Installments
No hidden fees – just official clinic prices. Pay at the clinic for KRAS, NRAS,BRAF mutation testing upon arrival and use a flexible instalment plan if needed.
Verified Clinics & Doctors Only
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in KRAS, NRAS,BRAF mutation testing and have the necessary licenses to serve international patients worldwide.
Free 24/7 Assistance
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your KRAS, NRAS,BRAF mutation testing journey.

Your personal Bookimed medical coordinator
- Supports you at every stage
- Helps choose the right clinic and doctor
- Ensures quick and convenient access to information
Best KRAS, NRAS,BRAF mutation testing Clinics in Istanbul: 13 Verified Options and Prices
Hisar Hospital Intercontinental
Mustafa Solak







Neolife Medical Center
Mehmet Salih Iyikesici



Dr. MED
Our Trusted Doctors
View all Doctors
Bulent Karagoz
Professor Bulent Karagoz is a medical oncologist at Anadolu Medical Center with a focus on tumor biology and immunology.
- Specializes in targeted therapy to attack specific molecules that help tumors grow
- Former Head of Medical Oncology at GATA Haydarpasa Training Hospital
- Authored over 40 scientific publications focused on immunotherapy and tumor research
- Certified in tumor biology by the Medical Oncology Association
- Uses KRAS, NRAS, and BRAF mutation testing to guide treatment for complex solid tumors

Abdulcabbar Kartal
Dr. Abdulcabbar Kartal is a certified Fellow of the European Board of Surgery. He specializes in gastrointestinal cancers where KRAS, NRAS, and BRAF mutation testing guides treatment.
- Treats stomach, colon, and small intestine cancers at Anadolu Medical Center
- Certified specialist in surgical endoscopy and advanced interventional endoscopic procedures
- Expert in HIPEC – uses heated chemotherapy to treat advanced metastatic cancers
- Member of the European Society of Coloproctology focused on rectal surgery
- Awarded Associate Professor title from Istanbul Okan University faculty of medicine

Huseyin Baloglu
Dr. Huseyin Baloglu is a pathologist at Anadolu Medical Center in Turkey. He leads liquid biopsy and precision oncology services. Dr. Baloglu holds a patent for molecular diagnostics in thyroid cancer treatment. He completed training at Albert Einstein College of Medicine and Heidelberg University.
- Authored over 600 peer-reviewed publications in molecular and surgical pathology.
- Specializes in tumor biopsy, immunohistochemistry, and genetic mutation testing.
- Treats complex oncological cases, including glioblastoma and rare sarcomas.
- Works at Anadolu Medical Center, a facility affiliated with Johns Hopkins Medicine.

Mehmet Salih Iyikesici
Dr. Mehmet Salih Iyikesici is a medical oncologist. His work focuses on metabolically supported chemotherapy (MSCT), ketogenic diet–supported cancer care, hyperthermia, hyperbaric oxygen therapy, and insulin potentiation therapy. He emphasizes care for breast, pancreatic, and gastric cancers.
He is a Medical Oncology Specialist at Neolife Medical Center (2026–present). He previously served at Private Bahçelievler Medical Park (2013–2026), Medicana Beylikdüzü (2010–2013), Silivri Anadolu (2009–2010), Diyarbakır Training and Research (2008–2009), and Bursa Çekirge State (2006–2008). Earlier, he worked as an Internal Medicine Specialist (1997–2003). He was an Assistant Professor at Altınbaş University (2014–2026).
Training: Medical Oncology subspecialty, Marmara University (2003–2006). Internal Medicine, Istanbul Haydarpaşa Numune (1992–1996). Medicine, Uludağ University (1985–1990). Member, Medical Oncology Association (since 2004). His recent research (2019–2020) covers gastric, breast, pancreatic, and lung cancers. Topics include long‑term survival in metastatic pancreatic cancer and feasibility in metastatic non‑small cell lung cancer (NSCLC).
Share this content
Anna Leonova






















